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Abstract
Background: Fear of cancer recurrence (FCR) has been shown to be higher in patients treated with external beam
radiotherapy (RT) compared to those untreated. However, little is known about the dynamics of patient’s FCR
during and after RT. The aim of this study was to examine FCR levels in a longitudinal panel design with breast
cancer patients receiving RT.
Methods: Consecutive newly-diagnosed breast cancer patients (n = 94) attending a single cancer centre were
invited to complete a 7-item FCR scale (FCR7) that was collected weekly by paper instrument and at a follow-up
phone call 6–8 weeks after completion of RT. Descriptive statistics, and Latent Growth Curve Modelling (LGCM)
were utilised to analyse the data.
Results: Women who were younger, single/separated, had chemotherapy, had extra boost radiation treatment,
taking Herceptin and treated by 4-field technique reported higher recurrence fear at baseline. There was strong
evidence of substantial variation in the trajectory of FCR (z = − 3.54, p < .0001). The average trajectory of FCR over RT
was negative (unstandardized estimate = − 0.59) and associated with FCR follow-up level (standardised
estimate = 0.36, z = 3.05, p < .002), independent of baseline recurrence fears.
Conclusion: Patients vary in their trajectory of recurrence fears over RT which predicts FCR approximately
2 months following treatment. Review appointments by therapy radiographers presents an opportunity to
intervene in FCR trajectories.
Trial registration: ClinicalTrials.gov: NCT02599506. Prospectively registered on 11th March 2015.
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Background
Breast cancer (BC) is the second most common cancer
in the world and the most frequent diagnosed cancer
among women [1]. The majority of patients diagnosed
with the disease undergo surgery, and a proportion
receive chemotherapy and radiotherapy (RT). These
treatments are frequently associated with significant psy-
chosocial difficulty across the lifespan [2]. Fear of cancer
recurrence (FCR) is one of the most common and aver-
sive psychological phenomena among breast cancer
patients [3]. It can be a concern for patients immediately
after diagnosis or treatment and has been shown to
remain stable for years [4].
Studies have shown that cancer patients “22 % to 87 %
reported moderate to high degree of FCR (on average 49
%)” [5], and 55–90% of breast cancer patients report
FCR throughout survivorship [6]. Cancer patients who
suffer from high FCR report negative behaviour change
(e.g. excessive personal checking behaviours and avoidance
behaviour) [7], increased health service use [8], inability to
plan for the future including work return [9] and significant
psychological distress, such as depression, anxiety and
post-traumatic stress symptoms [10–13].
A systematic review of 130 studies found that a number
of factors were associated with FCR [5]. Evidence showed
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that those at greater risk of FCR were survivors diagnosed
at a young age, female gender, and with higher education
level. Women diagnosed with cancer before age 50 were
more likely to suffer from FCR compared with their older
counterparts [14]. Various clinical factors, such as having
had a mastectomy or chemotherapy, and having more
physical symptoms have also been identified as strong
predictors of higher FCR. However, these findings are not
always consistent [15–19].
Radiotherapy is a treatment frequently used for cancer
patients involving the use of high-energy radiation [20].
Almost a half to two-thirds of cancer patients will have
radiotherapy as part of their treatment plan (adjuvant
treatment), and almost 75% of patients who received
radiotherapy are treated to cure the cancer, rather than
to relieve symptoms such as pain [21]. Radiotherapy is
delivered in two ways – external to the body by a linear
accelerator (external-beam radiation treatment, RT) or
within the body by judicious siting of radioactive seeds/
implants (brachytherapy, BT). According to the latest
data, about 88% of patients received RT while the
remaining 12% of patients received BT [20, 21].
To date, although studies have reported that cancer
patients may suffer from different psychological prob-
lems such as anxiety, depression as well as psychological
distress, in the course of RT [22, 23], there have been
few studies investigating the relationship between pa-
tient’s FCR and the receipt of RT. A previous systematic
review by Simard et al. [5] revealed a weak to moderate
relationship between cancer treatment type (surgery/
chemotherapy/ radiation treatment) and FCR, and a re-
cent meta-analysis [24] by our group, confirmed a weak
association between RT and FCR, however, the correl-
ation was found nonsignificant in breast cancer patients.
One study [25] has investigated FCR development over
the first 6 months from surgery but does not focus spe-
cifically on the final stage of treatment (radiotherapy)
where FCR first develops in earnest according to anec-
dotal reports. A longitudinal study by Manne et al. [26]
found that almost half of the participants diagnosed with
gynaecological cancer continued to experience a high
level of FCR (high-stable) 6 months after diagnosis, and
about 25% of the patients reported decreasing FCR over
time (high-decreasing) while the remaining 25% of the
sample reported consistently low FCR (low-stable)
throughout the 6-month period post diagnosis. A recent
report from the Netherlands followed patients soon after
primary breast cancer surgery and tracked FCR at base-
line, 6 months and 18 months follow up [27]. They
found that FCR levels were stable for the first 6 months
but at 1.5 years increased in younger compared to older
patients. These studies add important information on
the pattern of FCR following diagnosis but do not
concentrate, we believe, on a critical phase during the
patients’ time course namely at the point when RT is
provided, and subsequent in the short to medium term,
after the patient is discharged, from active hospital treat-
ment. Patients during RT typically report symptoms of
pain, skin problems and fatigue [28, 29]. According to
Leventhal’s self-regulation model [30] some patients may
misinterpret these symptoms to indicate disease progres-
sion rather than eradication, hence reflected in FCR
increase over the course of treatment. No study has
concentrated explicitly on FCR assessment at the RT
treatment phase and soon thereafter. Neither has atten-
tion been focused on the different levels of fractionation
received by patients with breast cancer. The majority of
patients at the specialist cancer unit receive ‘routine’ RT
treatment of 15 sessions. Patients with tumour margins
that are less distinct are treated with the addition of
RT with typically 4 ‘booster’ sessions, whereas DCIS
patients with non-invasive disease receive 23 sessions.
The clinical implications for patients’ FCR levels is
unknown. To investigate therefore this stage in the
patients’ ‘journey’ may assist our understanding of the
development of FCR. Therefore, longitudinal studies
on samples using a validated measure of FCR with
cancer patients are needed during this phase of the
treatment pathway [31, 32].
Aim
To investigate the behaviour of FCR across various
demographic and clinical related variables and the time
course of RT.
Objectives
1. To determine the effect of age, marital status, socio-
economic status, chemotherapy and radiotherapy
treatments, and self-reported comorbid conditions
on initial FCR levels.
2. To test the predictive ability of initial FCR and its
trajectory on 6–8 week follow up FCR level.
Methods
Participants and settings
All breast cancer patients were recruited from NHS
Lothian, Edinburgh Cancer Centre (ECC), Western
General Hospital. Patients were eligible if they were
female; above 18 years of age; scheduled to undergo
RT on the breast (+/− lymph nodes); and able to
read, write and understand English. Patients were ex-
cluded if they were male; deaf or required translators,
under age; or receiving palliative treatment. Patient
participation was voluntary. All data were collected
from March to September 2016.
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Instruments
A study specific set of questions (demographic/treat-
ment received sheet) were formulated to assess age (in
years), marital status, solitary living or with other(s),
education level, occupational status, treatment type and
technique, use of chemotherapy and/or Herceptin and
self-rated co-morbidity.
Fear of recurrence scale (FCR7)
This measure was developed to assess recurrence fears
and consists of items drawn from other FCR scales. It
has good psychometric qualities and has been used with
patients with breast, colorectal and head and neck
cancer [33]. Scores range from 6 (minimum) to 40 (ma-
ximum), providing an effective range of 34 units [34].
The validation data set was collected prior to this study
at the Edinburgh Cancer Centre including patients with
breast cancer (n = 206) and provides reference levels of
FCR for this scale. The reliability of the scale is good
with an internal consistency of 0.92 (95%CI: 0.90, 0.94)
and evidence for validity [34].
Procedure
The University of St Andrews and the NHS East of
Scotland Research Ethics Committee (NHS Lothian)
examined and approved the study (NRES No.: 13/ES/
0015). Study was registered on ClinicalTrials.gov (ID
No.: NCT02599506). All new patients diagnosed with
breast cancer attending the ECC during January to May
2016 were approached. During the patient’s pre-RT CT
scan visit, a clinical staff (radiographer, JC) first introduced
the study to the patient. For those women showing interest
in participating, the staff member introduced the patient to
the research assistant (YY), who met with the patients, ex-
plained the study in detail, and determined eligibility. Infor-
mation sheet was provided to the patient during the initial
research meeting. Written informed consent, demographic/
treatment received information and baseline FCR7 total
scores were obtained on the patient’s first treatment day
(FCR7 Week 1). Throughout the period of RT, patient was
asked to complete a weekly FCR7 scale (FCR7 Week 2 &
FCR7 Week3). On the final day of RT, patient was asked to
complete the FCR7 scale again (FCR7 Week4). Then, 6–8
weeks after the end of the treatment, all participants were
contacted by telephone to give their FCR7 ratings once
again (FCR7 Follow-up).
Data analysis
Descriptive statistics were utilized to characterize all
study covariates overall and FCR scores. Bivariate associ-
ations were investigated between sociodemographic,
clinical/treatment factors and baseline recurrence fear.
Individual and group average curves (routine, boost, and
DCIS groups) were plotted over the period that patients
were treated. Then, latent growth curve modelling
(LGCM) for longitudinal data was developed to test the
relationship of FCR over the time course of the treat-
ment [35–37]. Of specific interest was the association of
the initial FCR level (i.e. intercept) and the trajectory
(i.e. slope) with the outcome FCR assessed at 6–8 week
follow-up. A linear growth trajectory was proposed (i.e.
0–1–2–3). The limited sample size reduced our ability
to test more complex models. MPlus uses full informa-
tion maximum likelihood (FIML) estimation to exploit
comprehensively all data points. Statistical analyses were
conducted using SPSS Analytics software v.24 [38], and
MPlus8.0 [39]. Alpha was 0.05 for all tests (2-sided).
Results
Recruitment and data collection
Patient recruitment flowchart was showed in Fig. 1. A
total of 202 patients were approached after CT scan and
93 patients refused to participate in the study. The major
reasons for refusal were: not wanting to be reminded of
cancer (62%); not interested (19%); or too busy (9%). Fi-
nally, the total number of breast cancer patients enrolled
in the study was 97 (response rate, 48%). There were 68
breast +/− lymph nodes (routine treatment), 24 breast
+/−lymph nodes with boost treatment and the
remaining 5 were DCIS patients who had breast treated
alone. Three participants in the routine group withdrew
from the study after baseline assessment (data
destroyed), and two patients (one in routine group, and
one in boost group) failed to complete post-treatment
measurements. Of the 92 patients completing all assess-
ments during the treatment phase, 12 were lost to follow
up after 3 attempts to contact by telephone. A drop out
analysis demonstrated that on all demographic, treat-
ment and initial FCR levels the patients not followed up
were not significantly different (p > 0.3) from patients
with complete data. The exception was that 52% of
patients with full data claimed to have an additional
medical problem, whereas only 20% of the
non-followed up patients reported initially they had
this difficulty (p = 0.05).
Patient characteristics
Table 1 displays the patients’ baseline sociodemographic,
clinical/treatment characteristics. The mean age was
57.9 years (SD = 11.5, range: 28 to 85). On univariate
analysis, fear of cancer recurrence was associated with pa-
tient’s current age (p < .001) and marital status (p < .005).
Women who were younger and separated reported higher
cancer recurrence fear. Baseline mean fear scores did not
differ based on other sociodemographic factors, such as
education level, living alone vs with others and occu-
pational status. Other effects were demonstrated with
radiation treatment type (p = .006), treatment technique
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(p = .003), adjuvant chemotherapy (p < .001) and Hercep-
tin utilisation (p < .005). Patients who had extra boost ra-
diation treatment and those treated by 4-field technique
reported higher fear of recurrence. There were no sig-
nificant differences in baseline mean fear scores between
subjects with vs. without self-reported co-morbidity.
The average FCR levels for the sample across the 4
weekly ratings as 17.2 (SD 7.4) at baseline to 14.5 (SD
7.0) at week 4. The intervening weeks 2 and 3 returned
mean FCR levels of 15.6 (SD 7.6) and 15.0 (SD 7.4). The
range of values of the mean total scores remained vir-
tually at maximum across the weeks (i.e. 33 or 34). The
published normative mean value of the FCR7 with
patients with breast cancer (N = 206) was 16.96 (SD 6.9)
and with a 90% cut-off of 27 [34]. Our sample of partici-
pants rated as 11, 9, 7, 7% over the cut-off respectively
for the 4 weekly ratings [34].
FCR trajectory
The group average FCR curves over RT were plotted for
each of the three treatment groups (Fig. 2). Patients in
routine group, boost group and DCIS group were
treated 15 times, 19 times and 25 times, respectively.
We concentrated our analysis of trajectories on the
major two treatment groups (n = 87); routine (n = 64)
and boost (n = 23). Prior to fitting the LGCM the
Fig. 1 Patient recruitment flowchart
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covariances of the four weekly FCR totals (FCR7 Week 1
to FCR7 Week 4) were inspected. As illustrated by
Wickrama et al. we compared the range of covariances
in adjacent pairs of weekly observations (e.g. Week1 and
Week2, etc.) with non-adjacent pairs (e.g. Week1 and
Week3, etc.) [36]. Ratings assessed closer together
should exhibit higher values according to Wickrama’s
thesis. This was confirmed as shown by the adjacent
range values of 47.7 to 51.4 compared with the
non-adjacent range values of 41.2 to 47.9 and supporting
significant slope variation for explanation within the data
structure (page 19) [36]. On fitting the model it was con-
firmed that there was strong evidence of substantial vari-
ation in the trajectory of FCR (z = − 3.54, p < .0001). The
average trajectory of FCR over RT was negative
(unstandardized estimate = − 0.59) and associated with FCR
Table 1 Participant’s clinical and sociodemographic characteristics (N = 94)
Study Characteristic Value N (%) Mean FCR (SD) P
Sociodemographic
Age < 50 21 (22.3) 21.6 (8.7) .0001***
51–70 63 (67.0) 16.3 (6.3)
> 70 10 (10.6) 11.0 (6.2)
Marital Status Single 6 (6.4) 23.5 (11.3) .005**
Married 58 (61.7) 16.5 (6.4)
Separated 2 (2.1) 28.0 (4.2)
Partnered 12 (12.8) 18.1 (8.4)
Widowed 10 (10.6) 11.1 (5.3)
Divorced 6 (6.4) 17.8 (7.3)
Patient Live With Live Alone 17 (18.1) 16.9 (9.3) .878
Live with Partner 68 (72.3) 16.7 (6.7)
Live with Friend(s) 2 (2.1) 21.0 (12.7)
Live with Children 7 (7.4) 17.6 (9.8)
Education Level Left School at 16 50 (53.2) 16.4 (7.6) .545
Left School at 18 14 (14.9) 18.9 (6.4)
Have a University Degree 30 (31.9) 16.8 (7.8)
Occupational Status Full-time Employed 29 (30.9) 17.9 (7.2) .203
Part-time Employed 17 (18.1) 19.2 (9.7)
Retired 35 (37.2) 14.6 (6.5)
Temporarily unemployed 1 (1.1) 22.0
Housewife 12 (12.8) 17.8 (6.1)
Clinical factors
Rx Type Routine 65 (69.1) 15.8 (7.3) .006**
Routine + Boost 24 (25.5) 20.9 (6.7)
DCIS 5 (5.3) 13.0 (6.0)
Rx Technique 2 Field 74 (78.7) 16.1 (6.7) .003**
3 Field 9 (9.6) 15.0 (8.0)
4 Field 11 (11.7) 24.0 (8.4)
Chemotherapy Yes 39 (41.5) 20.4 (8.1) .0001***
No 55 (58.5) 14.5 (6.0)
Taking Herceptin Yes 8 (8.5) 23.9 (6.2) .005**
No 86 (91.5) 16.3 (7.3)
Other Med Problems Yes 44 (46.8) 15.4 (6.7) .060
No 50 (53.2) 18.3 (7.9)
Recurrence Scores; Rx: Radiation treatment
**p ≤ .005, ***p ≤ .0005
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follow-up level (standardised estimate = 0.36, z = 3.05,
p < .002), independent of baseline recurrence fears
(Fig. 3). The intercept (or baseline) was the strongest
predictor of FCR follow-up level (standardised esti-
mate = 0.68, z = 10.32, p < .0001). The overall fit of the
model was good (CFI = 0.97, SRMR = 0.066).
Discussion
This is the first study to examine in detail FCR levels
over the time course of RT and use the behaviour of ini-
tial levels and its trajectory to predict follow up FCR.
The results of the initial FCR ratings at the start of RT
confirmed previous reports, namely that FCR was less
with older compared with younger patients; that chemo-
therapy and Herceptin use was associated with increased
FCR [5]. Most women experienced a decline in fear dur-
ing and after RT. However, there was considerable vari-
ation of trajectories observed that warranted
explanation. Studies reveal that RT-induced side effects,
such as pain, tiredness and skin reaction, are common
and contribute to the symptom burden [40]. Chronic
and progressive side effects may be viewed by patients as
a constant reminder of their cancer or be misinterpreted
as an indicator of cancer recurrence, which leads to
Fig. 2 Weekly FCR7 trajectories for the 3 treatment groups: Routine (long dash), Booster (short dash), DCIS (solid line with dotted linear
regression line fitted)
Fig. 3 Latent Growth Curve Analysis model results. Latent variables shown as ellipses and raw scale values (FCR) in rectangular boxes. FCR7 Week
1 to FCR7 Week 4 denote FCR7 total scale values for the weekly ratings, FCR7 Follow-up denotes FCR7 total at 6–8 week follow up. Treatment
variable in grey-shaded rounded box. Residuals indicated by circles. Arrows show model fitted. Standardised coefficients presented. Significance
of structural model parameters shown using conventional symbols (** = p < 0.01; *** = p < .001) with width of path expanded according to
significance for ease of interpretation
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higher FCR scores. Besides, patients may hold doubts
about the efficacy of RT and feel afraid that they would
not receive the same intensive attention and care from
health professionals when at home. For those patients
who experience a downward (i.e. negative) fear trajec-
tory, one possible reason is that RT is usually the final
treatment they received for their disease (after a long
duration of treatment - surgery, chemotherapy and RT)
and patients may start to feel confident about their at-
tempt to return to normal life.
Patients in the group who received a boost reported
more fears than patients in the routine and DCIS
group. One explanation is that patients with a boost
may conclude that they have a more serious form of
breast cancer which requires more intensive treat-
ment. As mentioned previously this is not the case
and there may be an argument in favour of sharing
the issue of margins with patients in the decision to
perform the additional boost fractionation. DCIS pa-
tients report lower FCR levels compared to the other
two groups because their clinicians typically explain
that this condition is not as serious compared to
other forms of breast cancer.
The LGCM analysis showed clearly that the initial
level (intercept) was the strongest predictor of follow up
FCR into the first 2 months of ‘survivorship’. This find-
ing would tend to support the view that FCR is quite
stable and already present at the start of RT. Of interest
was the additional explanatory value of the trajectory
slope with follow up FCR, independent from baseline.
Hence patients who reported increasing levels of FCR
during the course of their RT would be more likely to
have a higher level of follow up FCR in comparison to
those with decreasing FCR, taking into account the
initial level of FCR. This finding, if replicated, would be
important new knowledge as it would demonstrate that
for an important group of patients whose concerns
about the cancer returning are already being promoted
in some way. It raises a crucial question of whether there
might be some intervention with these patients to inte-
rrupt such a process. Theoretically, according to
Leventhal’s self-regulation model [41], we can speculate
that patients may be identifying a particular side effect
or symptom that they dwell upon. These illness repre-
sentations potentially ‘fuel the fire’ of anxieties about
cancer returning at an early stage from diagnosis while
being treated. Intervention while staff are in close con-
tact may be recommended prior to patient discharge
from the service. Some initial support for this interpret-
ation has been identified [42].
Study limitations
The study was run in a single cancer centre in Scotland
limiting generalisation. Of those patients that were
initially approached approximately just over half partici-
pated. Just under 20% of patients were lost to follow up.
They were not significantly different from those that
remained on demographic, treatment or initial FCR level
variables. One exception out of the 13 tests conducted
to examine this drop out issue was that, at the 5% level,
patients who were lost to follow up tended not to report
additional health problems. Some caution would need to
be exercised when interpreting these findings. The DCIS
patients were excluded in the LGCM approach as they
were a small group of 5 patients and completed add-
itional ratings beyond 4 weeks due to their elongated
radiotherapy schedule. The sample size for conducting
latent variable estimation limited the control variables
other than treatment group assignment. The missing
data over the course of the treatment from participants
in the study were managed by the statistical approach
provided, and an efficient estimation procedure we
believe enabled reasonable conclusions to be drawn.
A further issue worthy of mention is ‘reactivity’, that
is, does inviting participants to rate their FCR weekly
sensitize them? We gave no desired expectation for
patients, that is encouraging a particular level or FCR
end state. One of the experts in the field of diary
methods has concluded that multiple assessments,
when there is no explicit goal presented to the re-
spondent, ‘does not seem to have a meaningful influ-
ence on their thoughts, feelings’ page 8 [43]. A
detailed discussion about this issue can be found [44]
and tests to investigate in detail in further studies are
warranted using ‘intentional missing-data designs’
[45]. In addition future work should concentrate on
running more observations of FCR across other cen-
tres to confirm that knowing a patient’s FCR trajec-
tory provides additional information to the baseline
FCR level to predict eventual FCR level at around
2 months after treatment. The LGCM approach used
does not allow for heterogeneity or clustering of
individual trajectories. Investigators are encouraged to
adopt a growth mixture model (GMM) coupled with
LGCM that would enable a more realistic attempt to
reflect patterns of trajectories in different ‘classes’ or
types of patients [36].
Clinical implications
Patients whose FCR changes during the course of RT
may be identified using simple rating scales or
well-chosen open questions at review appointments.
Attempts at listening to concerns such as these may be
crucial turning points to divert the process of FCR de-
velopment. The study of these sequential and dynamic
processes over time enables the clinical team to consider
approaches to intervene and prevent patients reflecting
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unduly or ruminating on symptoms or illness represen-
tations that may be inaccurate.
Conclusions
FCR at approximately 2 months from final treatment of
radiotherapy can be predicted reliably from their base-
line FCR rating, i.e. start of RT, and in addition from
their FCR trajectory during RT.
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